Results 31 to 40 of about 88,356 (287)

Assembly of pH-Responsive Antibody-Inspired Protein-Drug Conjugates

, 2021
With the advent of chemical strategies that allow the design of smart bioconjugates, peptide- and protein-drug conjugates are emerging as highly efficient therapeutics to overcome limitations of conventional treatment, as exemplified by antibody-drug ...
Seah Ling, Kuan, Michaela, Pieszka, Tao, Wang, Maksymilian Marek , Zegota, David Y. W. , Ng, Marco, Raabe, Tanja, Weil, Astrid , Heck, Lutz , Nuhn   +8 more
core   +1 more source

Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation

Medicine in Drug Discovery, 2022
Antibody–drug conjugates (ADC) utilizing the targeting properties of antibodies and therapeutic effects of drugs have emerged a rapid development in recent years.
Weiran Cao, Rui Li, Xing Pei, Meihong Chai, Lu Sun, Yuanyu Huang, Jiancheng Wang, Stefan Barth, Fei Yu, Huining He   +9 more
doaj   +1 more source

Additional file 2 of An amino acid transporter subunit as an antibody–drug conjugate target in colorectal cancer

, 2023
Additional file 2: Supplementary Fig. 2. A) Internalization of the anti-CD98hcECTO antibody in SW480 cells, analyzed by immunofluorescence. Scale bar = 25 μm.
Pandiella, Atanasio, Fernández-Barral, Asunción, Atanasio Pandiella (195056), Sayagués, José María, Sofía del Carmen (12277812), Mar Abad (121361), Montero, Juan Carlos, Muñoz Terol, Alberto, Antonio Barbáchano (16809289), Asunción Fernández-Barral (175687), Carmen, Sofía del, Barbáchano, Antonio, Juan Carlos Montero (12277806), Alberto Muñoz (16533), Abad, Mar, José M. Sayagués (16809286)   +15 more
core   +1 more source

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin

Clinical Medicine Insights: Oncology, 2012
Hodgkins lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb ...
Michelle Furtado, Simon Rule
doaj   +1 more source

Development, Validation and Application of a Bridging ELISA for Detection of Antibodies against GQ1001 in Cynomolgus Monkey Serum

Molecules, 2023
Immunogenicity is a major issue associated with the PK, efficacy, and safety evaluation of therapeutic protein products during pre-clinical and clinical studies. A multi-tiered approach consisting of screening, confirmatory, and titration assays has been
Tingting Liu, Yajun Sun, Xiaojie Deng, Lili Shi, Wenyi Chen, Wenjing Fang, Junliang Wu, Xiaotian Fan, Xiaoqiang Chen, Jianhua Sun, Gang Qin, Likun Gong, Qiuping Qin   +12 more
doaj   +1 more source

Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. [PDF]

, 2012
OBJECTIVE: To estimate the cost effectiveness of vaccinating people with high risk conditions against invasive pneumococcal disease using the 13 valent pneumococcal conjugate vaccine.
Edmunds, W. John, van Hoek, Albert Jan, Trotter, Caroline L, Rozenbaum, Mark H., C. L. Trotter, Miller, Elizabeth, Rozenbaum, Mark H, D. Fleming, Trotter, Caroline L., E. Miller, M. H. Rozenbaum, Edmunds, W John, W. J. Edmunds, Fleming, Douglas, A. J. van Hoek   +14 more
core   +1 more source

Novel method for screening functional antibody with comprehensive analysis of its immunoliposome

Scientific Reports, 2021
Development of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect.
Shusei Hamamichi, Takeshi Fukuhara, Izumi O. Umeda, Hirofumi Fujii, Nobutaka Hattori   +4 more
doaj   +1 more source

HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy

BIO Integration, 2023
Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (~150 kDa), which markedly slows diffusion through the ...
Yixia Liang, Rong Lei, Jiabao Tan, Junyue Fang, Lin Yu, Shiyu Tan, Yan Nie, Qiongchao Jiang, Xiaoyun Xiao, Phei Er Saw   +9 more
doaj   +1 more source

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer

Indian Journal of Medical and Paediatric Oncology, 2019
Docetaxel, trastuzumab, and pertuzumab, known as THP, is the preferred first-line treatment for HER2-positive advanced breast cancer, and the second-line drug of choice is trastuzumab emtansine.
Manikandan Dhanushkodi
doaj   +1 more source

Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches

Pharmaceuticals, 2021
In the last few decades, antibody-based diagnostic and therapeutic applications have been well established in medicine and have revolutionized cancer managements by improving tumor detection and treatment.
Ahmad Fawzi Hussain, Armin Grimm, Wenjie Sheng, Chaoyu Zhang, Marwah Al-Rawe, Karen Bräutigam, Mobarak Abu Mraheil, Felix Zeppernick, Ivo Meinhold-Heerlein   +8 more
doaj   +1 more source